DEEP RESEARCH · D&D PHARMATECH GLP-1 PLATFORM

[D&D Pharmatech] GLP-1 Pipeline Review Across Metabolic and Neurologic Disease

A high-risk, high-upside biotech review centered on DD01, ORALINK, Metsera, and NLY01

Written: 2025-07-02 · Biotech deep dive · Naver Blog

0. Bottom line first

Interpretation: The upside is large, but so is the risk. The central questions are whether DD01's rapid liver-fat reduction translates into fibrosis improvement, whether Metsera's oral obesity programs show differentiated food-effect, weight-loss, and tolerability data, and whether NLY01's EOPD pivot can secure a credible regulatory path.

1. Source materials and companion links

Related post: https://blog.naver.com/star_of_self/223919807948

Teacher video: https://youtu.be/iy5_KgLSNWk?si=jhZeIuu88YnDSt2S

Gemini audio MP3: Download D&D Pharmatech deep-dive MP3

2. Partnerships: technology validation and funding

Official fact: The Metsera partnership began in April 2023 and was expanded in March 2024, growing from an initial KRW 550 billion structure to total potential value above KRW 1 trillion. It covers six injectable and oral obesity/metabolic disease candidates: DD02S, DD03, DD14, DD07, DD15, and MET06. Reference: Metsera contract article

The deal includes upfront payments, development and commercialization milestones, and future sales royalties. Importantly, it also includes a research-service agreement under which Metsera funds D&D's preclinical development work for the licensed assets.

Official fact: D&D signed a license agreement worth up to $192 million with Shenzhen Salubris Pharmaceuticals for DD01 development and commercialization in Greater China. Salubris received Chinese IND approval for a Phase 1 obesity trial of DD01, designed to evaluate weight loss in patients without MASH or diabetes. Reference: Salubris IND article

Interpretation: The strategy is parallel: D&D advances DD01 mainly for MASH in the U.S., while a partner generates obesity data in China. This can validate multiple indications for one asset in a capital-efficient way while diversifying the U.S. MASH trial risk.

3. ORALINK: oral peptide delivery platform

ORALINK is not a single trick; it is a multi-component platform built to overcome the main barriers to oral peptide delivery. The source relies heavily on the company's ORALINK material. Reference: ORALINK company material

Official fact: The source states that ORALINK is protected by an expanding patent portfolio, including key patents obtained in Japan and Australia.

Interpretation: Novo Nordisk's oral semaglutide product Rybelsus uses SNAC, which creates a localized high-pH environment in the stomach to help absorption, but requires fasting, a small amount of water, and a 30-minute waiting period. If ORALINK can reduce or remove the food effect, convenience alone could become a major competitive advantage in oral GLP-1. The tradeoff is that a multi-component platform can create tougher CMC and large-scale manufacturing consistency challenges.

Beyond ORALINK, D&D has long-acting technology applied to DD01 and NLY01, intended to extend peptide half-life and allow weekly or less frequent injections. Its U.S. subsidiary Valted Seq uses the HiF-Seq platform to analyze human brain tissue databases and discover or validate targets in Parkinson's, Alzheimer's, and other neurodegenerative diseases.

4. DD01 MASH program: rapid fat reduction and the 48-week fibrosis event

Official fact: DD01 is a dual agonist of GLP-1 and glucagon (GCG) receptors. A U.S. Phase 2 trial in 67 patients met its 12-week primary endpoint. At week 12, 75.8% of DD01-treated patients achieved at least a 30% reduction in liver fat, compared with 11.8% on placebo, with p<0.0001. Mean liver-fat reduction was 62.3% for DD01 versus 8.3% for placebo. The discontinuation rate due to gastrointestinal adverse events was 9.1% in the DD01 arm. Reference: DD01 U.S. Phase 2 article

The source cautions that trial designs and patient populations differ, so the table should not be read as a direct head-to-head comparison.

Interpretation: DD01's 12-week liver-fat reduction speed is a strong signal. But the key FDA-relevant MASH endpoints are MASH resolution without fibrosis worsening and/or at least one-stage fibrosis improvement without MASH worsening. The expected 2026 48-week biopsy data is the main binary event for the program.

5. Oral obesity portfolio and NLY01

D&D licensed several ORALINK-based oral candidates to Metsera. The key assets are MET-224o and MET-097o, daily oral GLP-1 or multi-agonist peptides. The source expects initial Phase 1 data in 2025, especially early human weight-loss and tolerability data.

Interpretation: To compete, this portfolio needs to show at least one of three things: weight loss above 15-20%, clearly lower gastrointestinal adverse events, or reduced/eliminated food effect.

Official fact: NLY01 failed to meet the primary endpoint of MDS-UPDRS improvement in the overall population of a Phase 2 trial in 255 early untreated Parkinson's patients. A post hoc analysis found statistically significant and clinically meaningful motor-symptom improvement in patients under 60, a subgroup representing 37% of participants.

Interpretation: The company pivoted NLY01 toward early-onset Parkinson's disease. NIH and Cure Parkinson's collaboration may add credibility, but a regulatory path based on subgroup analysis from a failed study is risky. The source argues that until there is a clear FDA-agreed Phase 3 path, the program should carry a success probability below 10%.

6. Market opportunity and SOTP lens

• MASH: The source presents a broad 2030 global market outlook ranging from $30 billion, or about KRW 40-43 trillion, to higher estimates. The commercially important patients are F2-F3 fibrosis patients, matching DD01's target population.
• Obesity: The 2030 global market is forecast from $77 billion, or about KRW 100 trillion, to more than $100 billion, or about KRW 130-135 trillion.
• EOPD: The total Parkinson's drug market is forecast at $6.87-10.0 billion by 2030, and EOPD before age 50 is about 5-15% of PD cases. Applying that share gives an estimated EOPD market of about $340 million to $1.5 billion.

Interpretation: In an SOTP framework, DD01 is the asset whose probability of success can be re-rated sharply after 48-week fibrosis data. The Metsera portfolio should be valued through future milestone and royalty rNPV, while NLY01 currently contributes little but functions as a long-dated call option.

7. Strategic conclusion and inflection points

D&D Pharmatech has built a deep pipeline around the GLP-1 axis. Its strengths are the ORALINK platform, the risk-shared Metsera oral obesity program, and promising early DD01 data. The offsetting risks are the binary nature of DD01 fibrosis data, competition with global pharma leaders, the speculative nature of NLY01, and the financial pressure inherent to clinical-stage biotech.

1. Very important: DD01 MASH Phase 2 48-week biopsy data. The source treats 2026 as the key near-term catalyst.
2. Important: Metsera-partnered oral obesity Phase 1 data. Weight loss, safety, tolerability, and food effect for MET-224o/MET-097o are central.
3. Moderate: Salubris DD01 China Phase 1 obesity data.
4. Low: FDA discussions or Phase 3 design updates for NLY01 in EOPD.